These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 20035895

  • 1. NFATc1: functions in osteoclasts.
    Zhao Q, Wang X, Liu Y, He A, Jia R.
    Int J Biochem Cell Biol; 2010 May; 42(5):576-9. PubMed ID: 20035895
    [Abstract] [Full Text] [Related]

  • 2. Regulatory mechanism of NFATc1 in RANKL-induced osteoclast activation.
    Song I, Kim JH, Kim K, Jin HM, Youn BU, Kim N.
    FEBS Lett; 2009 Jul 21; 583(14):2435-40. PubMed ID: 19576893
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling.
    Yi T, Lee HL, Cha JH, Ko SI, Kim HJ, Shin HI, Woo KM, Ryoo HM, Kim GS, Baek JH.
    J Cell Physiol; 2008 Nov 21; 217(2):409-22. PubMed ID: 18543257
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL.
    Kim HN, Ha H, Lee JH, Jung K, Yang D, Woo KM, Lee ZH.
    Eur J Pharmacol; 2009 Nov 25; 623(1-3):22-9. PubMed ID: 19766111
    [Abstract] [Full Text] [Related]

  • 8. Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells.
    Mohamed SG, Sugiyama E, Shinoda K, Taki H, Hounoki H, Abdel-Aziz HO, Maruyama M, Kobayashi M, Ogawa H, Miyahara T.
    Bone; 2007 Oct 25; 41(4):592-602. PubMed ID: 17627913
    [Abstract] [Full Text] [Related]

  • 9. The molecular understanding of osteoclast differentiation.
    Asagiri M, Takayanagi H.
    Bone; 2007 Feb 25; 40(2):251-64. PubMed ID: 17098490
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.
    Kanazawa K, Kudo A.
    J Bone Miner Res; 2005 May 25; 20(5):840-7. PubMed ID: 15824857
    [Abstract] [Full Text] [Related]

  • 13. Identification of NFAT binding sites that mediate stimulation of cathepsin K promoter activity by RANK ligand.
    Balkan W, Martinez AF, Fernandez I, Rodriguez MA, Pang M, Troen BR.
    Gene; 2009 Oct 15; 446(2):90-8. PubMed ID: 19563866
    [Abstract] [Full Text] [Related]

  • 14. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
    Lee JH, Jin H, Shim HE, Kim HN, Ha H, Lee ZH.
    Mol Pharmacol; 2010 Jan 15; 77(1):17-25. PubMed ID: 19828731
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Lyn inhibits osteoclast differentiation by interfering with PLCgamma1-mediated Ca2+ signaling.
    Yoon SH, Lee Y, Kim HJ, Lee ZH, Hyung SW, Lee SW, Kim HH.
    FEBS Lett; 2009 Apr 02; 583(7):1164-70. PubMed ID: 19285079
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.